Characterization of the immune response of cattle against non-cytopathic and cytopathic biotypes of bovine viral diarrhoea virus

Michel Lambot, Alain Douart,[†] Eliane Joris,[‡] Jean-Jacques Letesson[§] and Paul-Pierre Pastoret

Department of Immunology/Vaccinology, Faculty of Veterinary Medicine, University of Liège, B43bis, B-4000 Sart Tilman–Liège, Belgium

Cross-infection studies of normal calves infected with homologous pairs of non-cytopathic and cytopathic bovine viral diarrhoea virus (BVDV) showed significant differences in both humoral and cell-mediated immune responses against either biotype over a period of 5 months. Serological assays after primary intranasal inoculation showed striking significant ($P < 0.05$) differences between biotypes. Neutralizing titres were detected earlier and were much higher with the non-cytopathic strain than with the homologous cytopathic strain. Significant biotype-specific differences were also observed in the lymphocyte proliferative responses of cattle following *in vitro* stimulation by non-cytopathic/cytopathic BVDV and the non-structural p80 protein (NS3). The secondary immune response seems to be largely influenced by the biotype used for the primary inoculation and only to a lesser extent by the biotype inoculated for the second time after an

interval of 91 days. Animals exposed twice to the cytopathic biotype, which exhibited the lowest antibody titres, showed evidence of BVDV-specific cell-mediated immunity as measured by lymphoproliferation against BVDV. In contrast, the antibody response in the subgroup of animals inoculated twice with homologous non-cytopathic virus was inversely correlated with the proliferative responses. These differences in the immune response were not readily apparent for the two other remaining subgroups which had received cytopathic or non-cytopathic biotypes alone following the second inoculation with non-cytopathic or cytopathic viruses, respectively. Taken together, these data suggest that the differences in immune responses against cytopathic or non-cytopathic strains may be due to a Th1/Th2-like regulatory mechanism.

Introduction

Bovine viral diarrhoea virus (BVDV) is a member of the genus *Pestivirus* within the family *Flaviviridae* (Westaway *et al.*, 1985). It is antigenically related to border disease virus of sheep and hog cholera virus (classical swine fever virus) of pigs. BVDV is distributed worldwide and is considered to be one of the most important viral pathogens of cattle although swine

and other ruminants are also susceptible (for a review see Paton, 1995).

Field BVDV isolates can be categorized into cytopathic or non-cytopathic biotypes according to their behaviour in cell culture (Baker, 1987; Adler *et al.*, 1994) and by the genomic rearrangements in the non-structural p125/p80 gene. The cytopathic biotype invariably expresses the NS3 protein, either by introducing a cleavage site in the NS23 protein expressed by the non-cytopathic biotype, or by duplication of the NS23 sequence encoding the NS3 protein (Donis & Dubovi, 1987*a*). Strains of the non-cytopathic biotype are routinely isolated from cases of acute infection and are invariably present in calves born persistently viraemic because of early transplacental infection (Liess *et al.*, 1974; McClurkin *et al.*, 1984). Such persistently infected animals generally succumb to fatal mucosal disease as a result of a natural superinfection with the cytopathic biotype derived from

Author for correspondence: Michel Lambot.

Fax +32 41 66 42 61. e-mail Lambot@stat.fmv.ulg.ac.be.

[†] Department of Medical Pathology, National Veterinary School of Nantes, Nantes, France.

[‡] Pfizer Central Research, Louvain-la-Neuve, Belgium.

[§] Department of Immunology, Faculties Notre Dame de la Paix, Namur, Belgium.

mutation of a persistent non-cytopathic strain (Brownlie *et al.*, 1987). This origin of the cytopathic virus explains the high level of antigenic similarity between a cytopathic/non-cytopathic virus pair isolated from the same animal (Howard *et al.*, 1987). It is generally accepted that humoral immunity plays a major role in protection against the disease. In experimental infection with BVDV, protection can be conferred through adoptive transfer of antibody to immunologically naive animals (Howard *et al.*, 1989; Shope *et al.*, 1976). Furthermore, cattle are considered to be immune to re-infection following their recovery from infection and the accompanying neutralizing antibody response (Pritchard, 1963). However, the roles played by either the non-cytopathic and/or cytopathic biotypes separately or interactively in the host's humoral immune response during the course of infection have not been investigated. Similarly, the impact and the role of the cellular immune response to BVDV in cattle have also not been studied in depth except for a few *in vitro* studies (Larsson & Fossum, 1992; Hooper *et al.*, 1992; Howard *et al.*, 1992). In these studies, where blood lymphocytes from seropositive animals were used, it was suggested that BoCD4⁺ cells play a pivotal role in the establishment of the immune memory to BVDV.

In this present report, we have attempted to characterize the immune response of cattle by comparing the qualitative and quantitative differences to a pair of non-cytopathic and cytopathic viruses in cross-infection studies by examination of the neutralizing antibody profiles and T cell proliferation. We also explored the proliferative response of cattle lymphocytes to a recombinant NS3 protein, as a preliminary study for detailed characterization of T cell recognition of BVDV proteins. The significance of the BVDV-specific immune responses reported here could be in their predictive value in assessment of natural or artificial protection against BVDV field virus infections.

Methods

Cells and viruses. An homologous pair of non-cytopathic and cytopathic strains, Pe 515, originally isolated at the AFRC Institute for Research on Animal Diseases, Compton, UK (Brownlie *et al.*, 1984) was kindly supplied by J. Brownlie, Royal Veterinary College, North Mymms, UK. The non-cytopathic strain was purified three times by terminal dilution while the cytopathic strain was plaque purified three times. The viruses were grown in calf testis (CT) cell cultures which were free of adventitious BVDV and maintained in OptiMEM medium (Gibco) supplemented with 10% heat-inactivated foetal calf serum treated with β -propiolactone. The non-cytopathic Pe 515 virus preparation was obtained after 5 days in culture by one freeze-thawing cycle and centrifugation at 3000 r.p.m. for 10 min to remove large cellular debris. The supernatant was then frozen at -80°C in aliquots until used for inoculation of calves and in *in vitro* assays. For the cytopathic Pe 515 virus preparation, BVDV-infected monolayers were prepared similarly and were harvested when 75% of cells showed a cytopathic effect. The supernatant from a non-infected CT cell culture, grown under similar conditions and treated as were the infected ones, was used as control. Titrations of viruses were

Fig. 1. Schematic representation of the inoculation procedure. Animals were divided into three groups in isolation units for the primary inoculation (at day 0) and were allotted to two isolation units for the challenge procedure at day 91. Based on their inoculation histories, all animals were divided into six subgroups: two subgroups in primary infection (C1 and C2) and four subgroups in challenge (A1–2 and B1–2). Arrows indicate time of both primary and secondary inoculations.

made in CT cell cultures and the TCID₅₀ was calculated according to Reed & Muench (1938). Non-cytopathic virus was detected by an immunofluorescent method.

Experimental design. A total of 18 calves, about 3 months old, which were both BVD virus- and BVDV-antibody negative were randomly allotted to two groups of seven (A and B) and one group of four (C) and housed in isolation units prior to primary inoculation. Animals were inoculated intranasally by spraying into each nostril 5 ml of culture medium containing 10^6 TCID₅₀ of virus/ml of the cytopathic (group A) and the homologous non-cytopathic (group B) Pe 515 strain. Animals in group C, used as negative controls, were each intranasally inoculated with virus-free cell culture medium.

Ninety-one days after inoculation, all calves were allotted to two isolation units and intranasally challenged with non-cytopathic or cytopathic Pe 515 strains as indicated in Fig. 1. The doses of inocula were the same as in primary inoculation. In the first unit, two control calves (group C), three calves from group A and three calves from group B were challenged with cytopathic BVDV. In the second unit, the remaining calves received the non-cytopathic counterpart of the BVDV strain used. Of these, two animals were from group C, four animals from group A and four from group B.

Blood samples were collected on the day of challenge and at 3 to 7 day intervals thereafter for a period of 10 weeks.

Preparation of recombinant BVDV NS3 protein. Construction and characterization of recombinant BVDV Osloss strain NS3 protein were recently described (Vanderheijden *et al.*, 1993). Briefly, the NS3 gene isolated from *NcoI*–*Bam*HI-restricted pARNS3 was inserted into the pACYM1 transfer vector. *Spodoptera frugiperda* insect cells (SF9) were co-transfected with the resulting pACVNS3 and wild-type *Autographa californica* nuclear polyhedrosis virus (AcNPV) DNA. For proliferation assays, recombinant NS3 antigen was produced from an AcNPVNS3-infected SF9 cell pellet which was lysed by three cycles of freeze-thawing, followed by sonication for 3×10 s, filtration through a $0.22 \mu\text{m}$ pore size

filter (Nalgene) and storage at -70°C until used. The identity of the NS3 protein and its purity (data not shown) were established as described by Vanderheijden *et al.* (1993).

■ **Neutralization assay.** The neutralizing activity of serum samples against 100 p.f.u. of cytopathic Pe 515 virus was determined by a microneutralization test (Lobmann *et al.*, 1986) with a few modifications. Neutralization titres are expressed as the reciprocal of the highest dilution resulting in a 50% reduction of BVDV plaques relative to the virus control.

■ **Lymphocyte proliferation assay.** Peripheral blood mononuclear cells (PBMC) were prepared on Ficoll-Hypaque (Pharmacia) as described by Letesson *et al.* (1985). PBMC were cultured in round-bottomed plates (Nunc) at 2.0×10^5 cells per well in RPMI 1640 medium supplemented with 10% heat-inactivated foetal calf serum, 1 mM sodium pyruvate, 2 mM glutamine, 25 mM HEPES, 50 μM 2-mercaptoethanol (2-ME), 0.5 μM amphotericin B, 100 IU/ml penicillin and 100 $\mu\text{g}/\text{ml}$ streptomycin.

The proliferative responses against non-cytopathic Pe 515 virus (1.0 TCID₅₀ per cell), the homologous cytopathic Pe 515 virus (0.5 TCID₅₀ per cell) and the recombinant BVDV NS3 protein were determined in sets of six wells. Cultures were incubated for 6 days at 37°C in 5% CO₂ and pulsed with [*methyl*-³H]thymidine (0.8 μCi ; sp. act. 2 Ci/mmol) (Amersham) for the last 18 h of culture. The cells were harvested onto glass filters with an automated cell harvester (Skatron) and the radioactivity on the filters was estimated with a scintillation counter (Betaplate 1205, Wallac). Non-infected CT cell culture at a similar dilution was used as a control. Results were expressed as a stimulation index (mean c.p.m. test sample/mean c.p.m. control). In the proliferation assays with soluble recombinant NS3 protein, a similar dilution of a filtrate from wild baculovirus-infected SF9 cells was used as a control. To control specificity, PBMCs from a BVDV-negative calf were included in all proliferation assays, and the stimulation index for each day over the period of the experiment was less than two in all cases (data not shown).

■ **Analysis of data.** Differences in neutralizing antibody and cellular responses between subgroups were analysed for statistical significance by Student's *t*-test.

Results

Antibody responses following BVDV inoculation

The pattern of development of neutralizing antibody within each of the six subgroups is shown in Fig. 2. The four control calves (C1 and C2), which had no antibody when exposed to BVDV, developed neutralizing antibody response with titres which were at least 1500 fold (Fig. 2). However, there was a significant difference between the kinetics of the antibody responses in calves inoculated with non-cytopathic virus and in those which received the cytopathic counterpart. Neutralizing activity was clearly detectable 1 week earlier in subgroup C2 than in subgroup C1 and the antibody response which was then reached was significantly higher ($P < 0.05$) in C2 compared with C1 for the remainder of the experiment. In the four other subgroups, challenge had no noticeable effect on the antibody response, regardless of the biotype used (Fig. 2). In terms of overall titres, calves first inoculated with non-cytopathic virus (B1 and B2) showed higher levels of neutralizing antibody than those which initially received

'homologous' cytopathic virus (A1 and A2), regardless of the biotype used in the challenge. However, these higher levels were only significant ($P < 0.05$) in the subgroup of animals inoculated twice with non-cytopathic virus (B1).

Lymphoproliferative response to BVDV

In a preliminary assay, the optimum virus dose for proliferation of PBMC stimulated with either biotype of strain Pe 515 was 1.0 TCID₅₀ per cell for the non-cytopathic virus and 0.5 TCID₅₀ per cell for its cytopathic counterpart (data not shown). Furthermore, maximum stimulation was induced using live virus preparations in cultures with 50 μM 2-ME and was observed at day 6 of proliferation (data not shown).

Fig. 3 shows the BVDV-specific proliferative responses in the six subgroups of calves after experimental inoculation. On primary inoculation with BVDV, significant ($P < 0.005$) cellular reactivity to virus was generated at 3 weeks, regardless of the biotype used (C1 and C2). The responsiveness to virus of the subgroups ncp and cp did not differ, either in the pattern or magnitude of proliferation. In contrast, a second inoculation 91 days after the first did not significantly affect the proliferative memory responses to virus in any subgroup of BVDV-immune calves (A1–2 and B1–2). At the time of challenge there was, however, a notable difference in the responses between subgroups depending on whether they had received the non-cytopathic or cytopathic biotype as a primary inoculum. The mean stimulation index for each subgroup given cytopathic virus first (A1 and A2) was significantly higher ($P < 0.05$) at day 91 than that of the two subgroups which were given non-cytopathic virus first (B1 and B2). Although the response fluctuated from week to week, this trend was consistent over the 10 week period of the experiment.

It should be noted that the pattern of the proliferative response of any subgroup to the cytopathic virus preparation closely resembled that induced by the non-cytopathic preparation although the magnitude of the responses was not as great as that seen with the non-cytopathic virus.

Response to recombinant BVDV NS3 protein

The lymphoproliferative response of calves to Osloss strain NS3 protein was tested at 1:30, 1:60 and 1:150 dilution of antigen. Fig. 4 shows the proliferation obtained at the optimum dose of 1:60 and indicates that recombinant NS3 protein was significantly recognized ($P < 0.05$) by lymphocytes from five of the six subgroups of calves (A1–2, B1 and C1–2). The magnitude of the responses was largely dependent on the biotype used at the last inoculation of the challenge experiment. A higher response was observed with lymphocytes from the subgroups of animals inoculated with non-cytopathic virus (A2, B1 and C2), compared with the response obtained in any subgroup exposed to the cytopathic counterpart (A1, B2 and C1).

Fig. 2

Fig. 2. Neutralizing antibody responses of calves after primary inoculation (C1 and C2) and after challenge (A1–2 and B1–2). Calves were first inoculated with cytopathic (●, ■, ▲) or non-cytopathic (○, □, △) BVDV and challenged (†) 91 days later with cytopathic (A1 and B2) or non-cytopathic (A2 and B1) virus. The mean antibody titres were expressed as the reciprocal of the serum dilution resulting in a 50% reduction of BVDV plaques relative to the virus control.

Fig. 3

Fig. 3. Effect of primary and secondary inoculation on the development of the *in vitro* proliferative response for PBMC of calves to non-cytopathic virus (○) and cytopathic counterpart (●). Calves were inoculated either once (C1 and C2) or twice (A1–2 and B1–2) according to the procedure described in Fig. 1. PBMC were cultured with non-cytopathic (1:0 TCID₅₀ per cell) or homologous cytopathic (0.5 TCID₅₀ per cell) Pe 515 virus preparations for 6 days and the results are expressed as a stimulation index.

Fig. 4. Comparison of the *in vitro* lymphocyte proliferative response of calves to recombinant NS3 protein after primary inoculation and after challenge. Calves were inoculated either once (C1 and C2) or twice (A1–2 and B1–2) according to the procedure described in Fig. 1. Arrows indicate time of both primary inoculation and challenge. PBMC were cultured with recombinant NS3 protein at 1:60 dilution. Proliferation is expressed as a stimulation index.

Discussion

In the present study, we chose to investigate the characteristics of the immune response of calves post-natally infected with a well-characterized pair of cytopathic and non-cytopathic BVDV strains (Pe 515) which were originally derived from a single animal (Brownlie *et al.*, 1984).

By sero-neutralization, it was first shown that the non-cytopathic biotype induced in the experimental animals a significantly more rapid and superior primary antibody response than the homologous cytopathic biotype. These higher neutralizing titres were maintained after the second inoculation, whatever biotype was used in the challenge. An inference drawn from the antibody response to BVDV is that biotype differences alone might result in differential humoral responses for the same virus strain pair. However, it will be essential to establish whether these effects observed with strain pair Pe 515 can be extended to other cytopathic and non-cytopathic strains. Previous investigations (House & Manley, 1973; Shope *et al.*, 1976; Howard *et al.*, 1989) emphasized the importance of immunoglobulins as mediators of immunity in BVDV re-infection. In contrast, cell-mediated immunity, known to be crucial in aiding recovery from many virus infections, has not been studied in depth for BVDV. For the pestivirus hog cholera virus, Rümenapf *et al.* (1991) showed that vaccinated animals with no neutralizing antibody titres often resist virus challenge, suggesting the involvement of mechanisms of protection other than antibodies.

Lymphocyte proliferation driven by specific antigen has been used as a means to define cellular reactivity to BVDV infection. On primary inoculation in calves, it has been shown that it is possible to induce memory T cells capable of

responding to a BVDV stimulation *in vitro*. The time-course of this response is similar to that seen in many other acute virus infections of young calves, contrary to the slow response in BVDV-specific antibody titres. There was no notable difference between both biotypes in the magnitude of the stimulation index obtained in the proliferation assays. The cellular response to challenge seems to be largely influenced by the biotype used in the primary exposure and only to a lesser extent by the biotype inoculated the second time. Lymphocyte reactivity of animals exposed to a cytopathic biotype at the first inoculation is significantly higher ($P < 0.05$) throughout the duration of the secondary response as compared to that of calves initially exposed to a non-cytopathic biotype.

Taken together, the data presented here highlight a difference in immune recognition by BVDV-infected animals, indicating that this recognition depends on the biotype of the strain pair involved. Hence, animals exposed at first to the non-cytopathic biotype, which exhibited significantly higher antibody titres, show a low secondary proliferative response against the virus whatever the biotype used in the secondary inoculation. In contrast, animals initially inoculated with the homologous cytopathic biotype have a high T cell reactivity during the secondary exposure to cytopathic or non-cytopathic viruses, despite the lower level of neutralizing activity seen in these calves. This distinction between humoral and cell-mediated responses would suggest the existence of distinct Th1 and Th2 subpopulations in the regulation of specific immune responses to BVDV, as recently described for bovine parasitic diseases (Brown *et al.*, 1994; Tetzlaff *et al.*, 1992). In order to determine the validity of the Th1/Th2 hypothesis, we are investigating the constitutive expression of two groups of cytokines, typical of the Th1 or Th2 cytokine

phenotypes, in cells isolated from a much larger group of calves infected with either biotype of BVDV.

The fact that non-structural proteins can be involved in the induction of cell-mediated responses and in resistance to infection (Gibson *et al.*, 1988) led us to examine *in vitro* T cell proliferative responses to NS3, one of the major non-structural polypeptides of BVDV. In this study, recombinant Osloss strain NS3 protein was recognized by lymphocytes from five of six experimental subgroups while non-cytopathic or cytopathic virus preparations were recognized in all calves infected. This suggests that other viral proteins may be important targets of T cell reactivity. It also suggests that while NS3 protein is an immunodominant antigen in the antibody responses of immunized calves (Donis & Dubovi, 1987*b*), this may not be true for T cell responses. Moreover, the subgroups of animals which received the non-cytopathic virus at the last inoculation developed the highest proliferative responses when compared with calves whose last inoculation was with cytopathic virus; the nature of the relationship between the ability to mount a T cell response to NS3 protein and the inoculation regime is not well understood. One may hypothesize that differences in the mode of interaction of the BVDV biotypes with host cells, related or not to a differential tissue tropism, could be the origin of the variation in the frequency of NS3-specific responder cells.

In conclusion, we have simultaneously evaluated the antibody and T cell responses of calves to two different biotypes of the same virus. Qualitative and quantitative differences in the immune response were demonstrated. Before drawing definite conclusions about the ability of BVDV biotypes to induce a differential immune mechanism, a final experimental infection with other pairs of cytopathic and non-cytopathic viruses should be combined with analysis of the expression of cytokines strictly limited to Th1- or Th2-type responses. If correct, the Th1/Th2 hypothesis will have important implications for vaccination against BVDV.

The authors wish to thank M. Loncar for skilful technical assistance and express their gratitude to Drs M. Denis, P. Hubert and J. Lyaku for helpful discussions and for reviewing the manuscript.

This work was supported by grants from the 'Institut pour l'encouragement de la Recherche Scientifique dans l'Industrie et l'Agriculture' (IRSIA).

References

- Adler, H., Perterhans, E. & Jungi, T. W. (1994). Generation and functional characterization of bovine bone marrow derived macrophages. *Veterinary Immunology and Immunopathology* **41**, 211–227.
- Baker, J. C. (1987). Bovine viral diarrhoea virus: a review. *Journal of the American Veterinary Medical Association* **190**, 1449–1458.
- Brown, W. C., Davis, W. C., Dobbelaere, D. A. E. & Rice-Ficht, A. C. (1994). CD4+ T-cell clones obtained from cattle chronically infected with *Fasciola hepatica* and specific for adult worm antigen express both unrestricted and Th2 cytokine profiles. *Infection and Immunity* **62**, 818–827.
- Brownlie, J., Clarke, M. C. & Howard, C. J. (1984). Experimental production of fatal mucosal disease in cattle. *Veterinary Record* **2**, 535–536.
- Brownlie, J., Clarke, M. C. & Howard, C. J. (1987). Clinical and experimental mucosal disease – defining a hypothesis for pathogenesis. In *Pestivirus Infections of Ruminants*, pp. 147–157. Edited by J. W. Harkness. CEC Seminar, Brussels, September 1985.
- Donis, R. O. & Dubovi, E. J. (1987*a*). Differences in virus-induced polypeptides in cells infected by cytopathic and noncytopathic biotypes of bovine virus diarrhoea-mucosal disease virus. *Virology* **158**, 168–173.
- Donis, R. O. & Dubovi, E. J. (1987*b*). Molecular specificity of the antibody responses of cattle naturally and experimentally infected with cytopathic and noncytopathic bovine viral diarrhoea virus biotypes. *American Journal of Veterinary Research* **48**, 1549–1554.
- Gibson, C. A., Schlesinger, J. J. & Barrett, A. D. T. (1988). Prospects for a virus non-structural protein as a subunit vaccine. *Vaccine* **6**, 7–9.
- Hooper, L. B., Clarke, M. C. & Brownlie, J. (1992). Lymphocyte proliferation in response to bovine viral diarrhoea virus antigen. *Proceedings of the Second Symposium on Pestivirus*, pp. 131–135, Annecy, France, 1–3 October.
- House, J. A. & Manley, M. (1973). Comments on passive immunity to bovine viral diarrhoea. *Journal of the American Veterinary Medical Association* **163**, 819–820.
- Howard, C. J., Clarke, M. C. & Brownlie, J. (1987). Comparisons by neutralisation assays of pairs of non-cytopathogenic and cytopathogenic strains of bovine virus diarrhoea virus isolated from cases of mucosal disease. *Veterinary Microbiology* **13**, 361–369.
- Howard, C. J., Clarke, M. C. & Brownlie, J. (1989). Protection against respiratory infection with bovine virus diarrhoea virus by passively acquired antibody. *Veterinary Microbiology* **19**, 195–203.
- Howard, C. J., Clarke, M. C., Sopp, P. & Brownlie, J. (1992). Immunity to BVDV in calves: the role of different T-cell subpopulations analysed by specific depletion *in vivo* with monoclonal antibodies. *Veterinary Immunology and Immunopathology* **32**, 303–314.
- Larsson, B. & Fossum, C. (1992). Bovine virus induces *in vitro* a proliferative response of peripheral blood mononuclear cells from cattle immunized by infection. *Veterinary Microbiology* **31**, 317–325.
- Letesson, J.-J., Lostrie-Trussart, N. & Depelchin, A. (1985). Production d'anticorps monoclonaux spécifiques d'isotypes d'immunoglobulines bovines. *Annales de Médecine Vétérinaire* **129**, 131–141.
- Liess, B., Frey, H.-R., Kittsteiner, H., Baumann, F. & Neumann, W. (1974). Observations and investigations on mucosal disease of cattle, a late stage of BVD-MD virus infection with immunobiological explanation and criteria of a slow virus infection. *Deutsche Tierärztliche Wochenschrift* **81**, 481–487.
- Lobmann, M., Charlier, P., Florent, G. & Zygraich, N. (1984). Clinical evaluation of a temperature-sensitive bovine viral diarrhoea vaccine strain. *American Journal of Veterinary Research* **45**, 2498–2503.
- McClurkin, A. W., Littledike, E. T., Cutlip, R. C., Frank, G. H., Coria, M. F. & Bolin, S. R. (1984). Production of cattle immunotolerant to BVD virus. *Canadian Journal of Comparative Medicine* **48**, 156–161.
- Paton, D. J. (1995). Pestivirus diversity. *Journal of Comparative Pathology* **112**, 215–236.
- Pritchard, W. R. (1963). The bovine viral diarrhoea-mucosal disease complex. *Advances in Veterinary Science* **8**, 1–47.
- Reed, L. J. & Muench, H. (1938). A simple method of estimating fifty percent endpoints. *American Journal of Hygiene* **27**, 493–497.
- Rümenapf, T., Stark, R., Meyers, G. & Thiel, H.-J. (1991). Structural proteins of hog cholera virus expressed by vaccinia virus: further

characterization and induction of protective immunity. *Journal of Virology* **65**, 586–597.

Shope, R. E., Muscoplat, C. C., Chen, A. W. & Johnson, D. W. (1976). Mechanism of protection from primary bovine viral diarrhea virus infection. I. The effects of dexamethasone. *Canadian Journal of Comparative Medicine and Veterinary Science* **40**, 355–359.

Tetzlaff, C. L., Rice-Ficht, A. C., Woods, V. M. & Brown, W. (1992). Induction of proliferative responses of T cells from *Babesia bovis*-immune cattle with a recombinant 77-kilodalton merozoite protein (Bb-1). *Infection and Immunity* **60**, 644–652.

Vanderheijden, N., De Moerlooze, L., Vandenberg, D., Chappuis, G., Renard, A. & Lecomte, C. (1993). Expression of the bovine viral diarrhoea virus Osloss p80 protein: its use as ELISA antigen for cattle serum antibody detection. *Journal of General Virology* **74**, 1427–1431.

Westaway, E. G., Brinton, M. A., Gaidamovich, S. Ya., Horzinek, M. C., Igarashi, A., Kaariainen, L., Lvov, D. K., Porterfield, J. S. & Trent, D. W. (1985). Togaviridae. *Intervirology* **24**, 125–139.

Received 14 December 1995; Accepted 17 December 1996